Valley National Bancorp’s Vertex Pharmaceuticals VRTX Stock Holding History

Valley National Bancorp’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$5K	Buy	+39	New	+$4.39K	0.01%	192

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Valley National Bancorp's VRTX Position: Q4 2014 in Review

Valley National Bancorp opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2014: 39 shares worth $5K. The stake represents 0.01% of the portfolio and ranks #192 among its holdings.

475 funds tracked by Wall St. Rank hold VRTX as of Q4 2014.

Valley National Bancorp held 39 shares of Vertex Pharmaceuticals worth $5K as of Q4 2014.
Vertex Pharmaceuticals was a new Valley National Bancorp position in Q4 2014.
Vertex Pharmaceuticals made up 0.01% of Valley National Bancorp's portfolio in Q4 2014, its #192 holding.
475 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2014.

Based on Valley National Bancorp's 13F filing for Q4 2014, filed 9 Feb 2015.